In this article the third Key Point was incorrectly given as: 'Data for children and subjects aged <65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.' but should have been: 'Data for children and subjects aged >65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.'. The original article has been corrected.
Correction to: Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan (Drugs, (2024), 84, 6, (661-684), 10.1007/s40265-024-02037-0)
Comberiati P.;
2025-01-01
Abstract
In this article the third Key Point was incorrectly given as: 'Data for children and subjects aged <65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.' but should have been: 'Data for children and subjects aged >65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.'. The original article has been corrected.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
